MPM BioImpact files 8.8% stake in DBV Technologies

DBV Technologies S.A. ownership update: MPM BioImpact LLC reports beneficial ownership of 26,066,806 Ordinary Shares, equal to 8.8% of the outstanding Ordinary Shares.

Rhea-AI Filing Summary

DBV Technologies S.A. ownership update: MPM BioImpact LLC reports beneficial ownership of 26,066,806 Ordinary Shares, equal to 8.8% of the outstanding Ordinary Shares. The filing states the outstanding Ordinary Shares were 296,042,447 as of March 31, 2026. The report is signed by Christopher Wolf, Chief Financial Officer.

Insights

Corporate Governance Analyst

MPM BioImpact reports an 8.8% stake in DBV Technologies.

The filing shows 26,066,806 Ordinary Shares beneficially owned by MPM BioImpact LLC, representing 8.8% of 296,042,447 outstanding shares as of March 31, 2026. Ownership is reported with sole voting and dispositive power.

Because this is an ownership disclosure amendment, its immediate impact is disclosure-only; subsequent filings would show any changes to holdings or intentions.

Key Figures

Shares beneficially owned: 26,066,806 shares Percent of class: 8.8% Outstanding Ordinary Shares: 296,042,447 shares +3 more

6 metrics

Shares beneficially owned 26,066,806 shares reported beneficial ownership by MPM BioImpact LLC

Percent of class 8.8% percentage of Ordinary Shares owned as of March 31, 2026

Outstanding Ordinary Shares 296,042,447 shares outstanding Ordinary Shares as of March 31, 2026

ADS conversion ratio 1 ADS = 5 Ordinary Shares stated ADS-to-Ordinary Share relationship

CUSIP 23306J309 CUSIP assigned to the Issuer's ADSs

Sole voting/dispositive power 26,066,806 shares shares for which MPM BioImpact reports sole power

Key Terms

American Depositary Shares (ADSs), Beneficially owned, Sole dispositive power

3 terms

American Depositary Shares (ADSs) financial

"Each ADS represents five Ordinary Shares."

A U.S.-listed certificate that stands for a specific number of shares in a non‑U.S. company held by a U.S. bank, making the foreign stock tradable on American exchanges in dollars. Think of it like a local voucher that represents ownership of an overseas product — it lets U.S. investors buy and sell foreign companies without handling foreign currency or foreign brokerage accounts, but it can affect dividends, voting rights, fees, liquidity and exposure to currency and regulatory differences.

Beneficially owned regulatory

"Amount beneficially owned: There is no CUSIP number assigned to the Ordinary Shares."

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

Sole dispositive power regulatory

"Sole power to dispose or to direct the disposition of: 26,066,806"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake does MPM BioImpact LLC hold in DBVT?

MPM BioImpact LLC beneficially owns 26,066,806 Ordinary Shares, representing 8.8% of DBV Technologies' Ordinary Shares as of March 31, 2026. The figure includes shares represented by ADSs.

How many DBV Ordinary Shares were outstanding as of March 31, 2026?

The filing states there were 296,042,447 Ordinary Shares outstanding as of March 31, 2026. The ownership percentage for MPM BioImpact is calculated using this outstanding share count.

Do the reported shares include ADSs for DBV Technologies (DBVT)?

Yes. The report notes a CUSIP for the ADSs and states each ADS represents five Ordinary Shares; the reported total includes 26,066,805 Ordinary Shares represented by ADSs plus one Ordinary Share.

What voting and disposition powers does MPM BioImpact report?

MPM BioImpact reports sole voting power for 26,066,806 shares and sole dispositive power for 26,066,806 shares, with no shared voting or dispositive power listed.

Who signed the Schedule 13G/A for MPM BioImpact?

The Schedule 13G/A is signed by Christopher Wolf, identified as Chief Financial Officer, with the signature date of May 15, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/15/2026 - 04:09 PM EDT Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

DBV TECHNOLOGIES S.A.

(Name of Issuer)

Ordinary Shares, nominal value 0.10 euro per share

(Title of Class of Securities)

23306J309

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 23306J309

1

Names of Reporting Persons

MPM BioImpact LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 26,066,806.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 26,066,806.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

26,066,806.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

8.8 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: DBV TECHNOLOGIES S.A.
(b)	Address of issuer's principal executive offices: 177-181 AVENUE PIERRE BROSSOLETTE, MONTROUGE, I0, 92120.
Item 2.
(a)	Name of person filing: MPM BioImpact LLC
(b)	Address or principal business office or, if none, residence: 399 Boylston Street, Suite 1100 Boston, MA 02116
(c)	Citizenship: Delaware
(d)	Title of class of securities: Ordinary Shares, nominal value 0.10 euro per share
(e)	CUSIP No.: 23306J309
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: There is no CUSIP number assigned to the Ordinary Shares. CUSIP number 23306J309 has been assigned to the American Depositary Shares ("ADSs") of the Issuer. Each ADS represents five Ordinary Shares. The shares reported herein for the Reporting Person include (i) 1 Ordinary Share, and (ii) 26,066,805 Ordinary Shares represented by ADSs. The information required by this item with respect to the Reporting Person is set forth in Rows 5 through 9 and 11 of the cover page to this Schedule 13G. The beneficial ownership percentage reported is based on 296,042,447 outstanding Ordinary Shares as of March 31, 2026, as disclosed in the Company's Form 10-Q filed April 30, 2026.
(b)	Percent of class: As of March 31, 2026, the Reporting Person beneficially owned 8.8% of the Ordinary Shares.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 26,066,806
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 26,066,806
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

MPM BioImpact LLC

Signature:	Christopher Wolf
Name/Title:	Chief Financial Officer
Date:	05/15/2026